KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Non-Current Debt (2016)

Vertex Pharmaceuticals (VRTX) has 5 years of Non-Current Debt data on record, last reported at $74.9 million in Q2 2016.

  • For Q2 2016, Non-Current Debt fell 70.26% year-over-year to $74.9 million; the TTM value through Jun 2016 reached $74.9 million, down 70.26%, while the annual FY2015 figure was $223.9 million, 20.21% down from the prior year.
  • Non-Current Debt reached $74.9 million in Q2 2016 per VRTX's latest filing, down from $149.6 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $294.8 million in Q3 2015 and bottomed at $74.9 million in Q2 2016.
  • Average Non-Current Debt over 3 years is $229.6 million, with a median of $259.1 million recorded in 2015.
  • Peak YoY movement for Non-Current Debt: grew 0.03% in 2015, then plummeted 70.26% in 2016.
  • A 3-year view of Non-Current Debt shows it stood at $280.6 million in 2014, then dropped by 20.21% to $223.9 million in 2015, then tumbled by 66.53% to $74.9 million in 2016.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $74.9 million in Q2 2016, $149.6 million in Q1 2016, and $223.9 million in Q4 2015.